What is Lincoln Pharmaceuticals Ltd (LINCOLN) share price return in the past 10 years?

Lincoln Pharmaceuticals Ltd share price has appreciated 15.6% annually (CAGR) over the past ten years.

What is the share price of Lincoln Pharmaceuticals Ltd (LINCOLN)?

Company share prices are keep on changing according to the market conditions. The current trading price of Lincoln Pharmaceuticals Ltd (LINCOLN) on 04-Jun-2026 16:59:59 at 16:59 is 619.90.

What is the P/E ratio of Lincoln Pharmaceuticals?

The latest standalone P/E ratio of Lincoln Pharmaceuticals as of 04-Jun-2026 is 14.13.

What is the P/B ratio of Lincoln Pharmaceuticals Ltd (LINCOLN)?

The latest standalone P/B ratio of Lincoln Pharmaceuticals Ltd (LINCOLN) as of 04-Jun-2026 is 1.64.

What is the 52-week high and low of Lincoln Pharmaceuticals Ltd (LINCOLN)?

The 52-week high of Lincoln Pharmaceuticals Ltd (LINCOLN) is Rs. 770.00 and the 52-week low is Rs. 439.95.

Lincoln Pharmaceuticals Ltd (LINCOLN) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Lincoln Pharmaceuticals Ltd (LINCOLN)
Brand: Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Ltd (LINCOLN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531633 NSE: LINCOLN Pharmaceuticals & Drugs | Small Cap | Lincoln Pharma Share Price

Lincoln Pharmaceuticals Ltd (LINCOLN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531633 NSE: LINCOLN Pharmaceuticals & Drugs | Small Cap | Lincoln Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹1,242 Cr.

Current Price

₹619.9

52-Week Low / High

₹440 / 770

TTM EPS

₹43.9

TTM Sales

₹671 Cr.

Book Value per Share

₹378.3

P/E Ratio

14.13

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

1.64

In line with its 5-year historical median

Price to Sales (P/S)

1.85

Higher than its 5-year historical median

EV/EBITDA

9.26

Higher than its 5-year historical median

Dividend Yield

0.33%

Profitability Efficiency

Return on Equity (ROE)

13.02%

Outperforms industry median

Return on Capital Employed (ROCE)

17.55%

Outperforms industry median

Return on Assets (ROA)

10.65%

Operating Profit Margin

16.3%

Net Profit Margin

13.21%

Gross Profit Margin

18.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

7.35%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

1.58%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-11.74%

Asset Quality

Promoter Holding

49.78%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹738 Cr.

Equity

₹20 Cr.

Face Value

₹10

All Time Low / High

₹8.05 / 975.00

Lincoln Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Lincoln Pharmaceuticals Ltd a good quality company?

Lincoln Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Lincoln Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Lincoln Pharmaceuticals Ltd vs industry peers?

Lincoln Pharmaceuticals Ltd revenue CAGR is 10.63%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Lincoln Pharmaceuticals Ltd?

Promoters hold 49.78% of the Lincoln Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Lincoln Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 17.8% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	19.8%	18.6%	18.3%	21.7%	21.8%	25.2%	24.3%	21.8%	22.5%	17.6%	-
Value Creation Index ⓘ	0.4	0.3	0.3	0.6	0.6	0.8	0.7	0.6	0.6	0.3	-
Growth Parameters ⓘ
Sales ⓘ	311	304	325	353	376	423	472	510	581	623	671
Sales YoY Gr.	-	-2.1%	6.8%	8.6%	6.5%	12.5%	11.6%	8.1%	13.8%	7.4%	-
Adj EPS ⓘ	12.2	13.6	15.1	21.8	21.6	30.7	33.9	32.3	44.5	37.4	43.9
YoY Gr.	-	11.8%	10.8%	44.5%	-0.9%	42.1%	10.5%	-4.7%	37.6%	-15.9%	-
BVPS (₹) ⓘ	80.4	94.8	109.8	131.3	152.3	182.9	216.1	250.9	296	335.3	378.3
Adj Net Profit ⓘ	19.9	27.2	30.2	43.6	43.2	61.5	68	64.8	89.1	75	88
Cash Flow from Ops. ⓘ	28.9	17.8	21.3	51.1	70.7	69.4	76.2	39.2	63.2	93	-
Debt/CF from Ops. ⓘ	2.1	3	2.6	0.7	0.1	0	0	0.1	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8%	10.6%	9.7%	7.4%
Adj EPS ⓘ	13.3%	11.6%	3.4%	-15.9%
BVPSⓘ	17.2%	17.1%	15.8%	13.3%
Share Price	15.6%	16.5%	17.9%	8.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	15.9	16.6	14.8	18.1	15.2	18.3	17	13.9	16.3	11.9	12.3
Op. Profit Mgn % ⓘ	10.6	14	14.2	17.1	15.9	20.6	20.3	17.5	17.3	16.3	14.6
Net Profit Mgn % ⓘ	6.4	9	9.3	12.4	11.5	14.6	14.4	12.7	15.4	12	13.1
Debt to Equity ⓘ	0.5	0.3	0.3	0.1	0	0	0	0	0	0	0
Working Cap Days ⓘ	168	198	221	223	227	227	226	231	224	232	110
Cash Conv. Cycle ⓘ	93	93	94	90	80	63	64	79	85	76	81

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	311	304	325	353	376	423	472	510	581	623
Operating Expenses ⓘ +	278	262	279	293	317	336	377	421	481	522
Manufacturing Costs	29	32	39	45	48	69	78	96	114	133
Material Costs	189	158	152	157	163	155	170	179	204	203
Employee Cost	27	35	48	48	55	63	80	93	103	112
Other Costs ⓘ	34	37	41	42	50	49	50	53	60	73
Operating Profit ⓘ	33	42	46	60	59	87	95	89	100	101
Operating Profit Margin (%)	10.5%	13.9%	14.1%	17.1%	15.8%	20.6%	20.2%	17.5%	17.2%	16.3%
Other Income ⓘ +	6	3	6	7	12	6	10	22	34	22
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	6	5	4	4	2	2	1	2	1	2
Depreciation ⓘ	3	4	4	5	5	8	8	9	11	13
Profit Before Tax ⓘ	30	36	43	58	64	84	96	100	122	109
Tax ⓘ	8	8	10	12	14	21	27	28	29	27
Profit After Tax	22	27	33	47	50	62	69	73	93	82
PAT Margin (%)	7.0%	9.0%	10.1%	13.2%	13.2%	14.7%	14.7%	14.3%	16.1%	13.2%
Adjusted EPS (₹)	13.3	13.7	16.4	23.3	24.8	31.1	34.6	36.4	46.6	41.1
Dividend Payout Ratio (%)	7.50%	8.80%	9.20%	6.40%	6.10%	4.80%	4.30%	4.10%	3.90%	4.40%

Valuation of Lincoln Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	131	190	220	263	304	366	433	502	593	672
Share Capital ⓘ	16	20	20	20	20	20	20	20	20	20
Reserves ⓘ	115	170	200	243	284	346	413	482	573	652
Debt +	59	51	55	32	4	0	2	2	1	0
Long Term Debt	9	7	6	2	1	0	0	0	0	0
Short Term Debt	50	44	49	30	4	0	2	2	1	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	21	25	35	36	42	57	71	51	72	85
Others Liabilities ⓘ	31	33	32	47	61	78	79	81	59	65
Total Liabilities ⓘ	242	299	341	378	412	501	585	636	725	822
Fixed Assets
Net Fixed Assets ⓘ +	63	68	83	88	91	111	132	151	179	182
Gross Block	80	72	91	101	108	142	171	197	237	252
Accumulated Depreciation	17	4	8	12	17	31	39	47	57	70
CWIP ⓘ	3	7	0	2	0	2	16	7	3	4
Investments ⓘ	20	36	39	46	60	81	97	91	139	174
Inventories	25	32	36	29	38	47	73	70	77	79
Trade Receivables	75	79	96	113	91	112	115	135	161	166
Cash Equivalents	5	5	8	7	11	13	18	34	13	22
Others Assets ⓘ	51	72	78	91	121	136	134	148	152	195
Total Assets ⓘ	242	299	341	378	412	501	585	636	725	822

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	29	18	21	51	71	69	76	39	63	93
PBT ⓘ	30	36	43	58	64	84	96	100	122	109
Adjustment ⓘ	8	8	8	7	5	5	1	-0	-17	1
Changes in Working Capital ⓘ	-3	-17	-21	3	15	0	2	-31	-16	9
Tax Paid ⓘ	-6	-9	-9	-17	-14	-19	-24	-30	-26	-26
Cash Flow From Investing Activity ⓘ +	-40	-26	-14	-22	-29	-64	-78	-37	-57	-79
Capex	-33	-17	-9	-11	-6	-9	-45	-14	-40	-19
Net Investments	0	-10	1	-6	-15	-44	-23	-4	-3	-30
Others ⓘ	-7	1	-5	-5	-8	-11	-9	-19	-15	-30
Cash Flow From Financing Activity ⓘ +	11	8	-4	-30	-38	-6	-3	-5	-5	-6
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	8	-2	-1	-4	-3	-1	-1	0	0	0
Interest Paid ⓘ	-6	-5	-4	-4	-2	-1	-1	-1	-1	-2
Dividend Paid ⓘ	-2	-2	-3	-4	-7	0	-3	-3	-3	-4
Others ⓘ	10	17	4	-18	-26	-4	2	-0	-1	-1
Net Cash Flow ⓘ	-0	-0	4	-1	4	-1	-4	-2	1	8

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	17.94	17.09	16.01	19.35	17.48	18.56	17.35	15.59	17.04	13.02
ROCE (%)	19.83	18.63	18.28	21.68	21.81	25.21	24.29	21.82	22.53	17.55
Asset Turnover Ratio	1.45	1.14	1.02	1.01	0.99	0.96	0.91	0.88	0.89	0.84
PAT to CFO Conversion(x)	1.32	0.67	0.64	1.09	1.42	1.11	1.1	0.53	0.68	1.13
Working Capital Days
Receivable Days	90.90	91.50	98.30	104.80	95.70	84.80	83.50	85.50	89.10	91.30
Inventory Days	25.40	33.50	38.30	33.10	31.40	35.10	43.90	48.70	44.30	43.60
Payable Days	32.70	52.60	72	82.50	87	116	137.60	124.20	110	141.50

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lincoln Pharmaceuticals Ltd FAQs

The current trading price of Lincoln Pharma on 04-Jun-2026 16:59 is ₹619.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Lincoln Pharma stood at ₹1,241.6 Cr

The latest P/E ratio of Lincoln Pharma as of 03-Jun-2026 is 14.13.

The latest P/B ratio of Lincoln Pharma as of 03-Jun-2026 is 1.64.

The 52-week high of Lincoln Pharma is ₹770.0 and the 52-week low is ₹439.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lincoln Pharma is ₹671 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Lincoln Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Lincoln Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Lincoln Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals was established in 1979 to manufacture and market affordable therapeutic products. Since then, Lincoln Pharmaceuticals has come a long way.

Lincoln Pharmaceuticals is a public limited company with a large shareholder base including members of the medical fraternity. It has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters. There are three different buildings for tablets, capsules and injectables and also a separate building for quality control.

An ultramodern laboratory with state-of-the-art equipments ensures in-house quality assurance of each of the products. The products are designed for all therapeutic segments with a special emphasis on gynecological and orthopedic specialties.

Group of Companies

Lincoln Parenterals
Karnavati Distributors
Down Town Travels
Shelavi Paper Mills

Product of the company

Tablets
Capsules
Injectables
Syrups
Ointments

Certification

WHO-GMP standard
ISO 9002 certification
Export House certification

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Lincoln Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lincoln Pharmaceuticals Ltd FAQs

About Lincoln Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals Ltd (LINCOLN)

Lincoln Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Lincoln Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lincoln Pharmaceuticals Ltd FAQs

What is the share price of Lincoln Pharma?

What is the market cap of Lincoln Pharma?

What is the P/E ratio of Lincoln Pharma?

What is the P/B ratio of Lincoln Pharma?

What is the 52-week high and low of Lincoln Pharma?

What is the TTM revenue of Lincoln Pharma?

Is Lincoln Pharmaceuticals Ltd a good quality company?

Is Lincoln Pharmaceuticals Ltd undervalued or overvalued?

Is Lincoln Pharmaceuticals Ltd a good buy now?

About Lincoln Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.